Biography
Dr. David Amron is a board-certified dermatologic surgeon with over 25 years of experience and is internationally recognized as one of the leading specialists in lipedema reduction surgery, liposculpture, and revision liposuction. He is the Founder and Medical Director of The Roxbury Institute, with locations in Beverly Hills, California; Tucson, Arizona; and Salt Lake City, Utah, where he focuses exclusively on the surgical treatment of lipedema.
Throughout his career, Dr. Amron has performed more than 12,000 surgical procedures and has dedicated his practice to advancing the science and technique of lymph-sparing lipedema surgery. He works closely with Dr. Karen Herbst, Ph.D., M.D., Head of Research and Director of Diagnostic and Preventative Medicine for the Advanced Lipedema Treatment program at The Roxbury Institute, integrating surgical expertise with ongoing research and clinical insight.
Dr. Amron earned his degree in Biology from the University of California, San Diego, followed by his medical degree from the Albert Einstein College of Medicine in New York. He completed his residency at UCSD and a research fellowship at UCLA. He is board-certified by the American Board of Dermatology and is an active member of multiple professional organizations, including the American Society for Dermatologic Surgery and the American Society for Liposuction Surgery.
An international educator and surgical advisor, Dr. Amron trains select surgeons worldwide in his specialized techniques and has been widely featured in national and international media. He is the creator and host of Lippy Logic™, one of the first comprehensive educational YouTube series dedicated to lipedema, and he is a vocal advocate for patient education and insurance reform.
In 2023, Dr. Amron released his bestselling book, Liposculpture and Lipedema Surgery: A Guide for the Patient and Pearls for the Surgeon, further solidifying his commitment to patient-centered care and surgical precision. His work continues to shape the standard of care for lipedema patients globally.
